MISOPROSTOL COADMINISTERED WITH DICLOFENAC FOR PREVENTION OF GASTRODUODENAL ULCERS - A ONE-YEAR STUDY

Citation
Nm. Agrawal et al., MISOPROSTOL COADMINISTERED WITH DICLOFENAC FOR PREVENTION OF GASTRODUODENAL ULCERS - A ONE-YEAR STUDY, Digestive diseases and sciences, 40(5), 1995, pp. 1125-1131
Citations number
25
Categorie Soggetti
Gastroenterology & Hepatology
ISSN journal
01632116
Volume
40
Issue
5
Year of publication
1995
Pages
1125 - 1131
Database
ISI
SICI code
0163-2116(1995)40:5<1125:MCWDFP>2.0.ZU;2-G
Abstract
The objective of this study was to determine the long-term efficacy of misoprostol in preventing diclofenac-induced gastroduodenal ulcers in rheumatoid arthritis and osteoarthritis patients. Three hundred eight y-four patients who had an endoscopically confirmed gastric or duodena l lesion that had healed with misoprostol therapy were randomized to r eceive misoprostol or placebo coadministered with diclofenac for up to 52 weeks. Endoscopic examinations were repeated at weeks 12, 24, and 52. The development of a gastric and/or duodenal ulcer was considered a prophylaxis failure. Results in the evaluable cohort of patients dem onstrated that gastroduodenal ulcer incidences were lower with misopro stol than placebo for all study periods (0-12 weeks, 7% vs 23%; 0-24 w eeks, 11% vs 26%; and 0-52 weeks, 15% vs 31%). Misoprostol did not int erfere with the antiarthritic effects of diclofenac. In conclusion, mi soprostol coadministered with diclofenac for 12 months to patients wit h rheumatoid arthritis or osteoarthritis significantly reduced the inc idence of diclofenac induced gastroduodenal ulcers (P less than or equ al to 0.018).